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Objective/background: The use of computed tomography pulmonary angiography (CTPA) in
the emergency department (ED) for patients suspected to have pulmonary embolism (PE) has
been steadily rising in the last 2 decades. However, there are limited studies that specifically
address the use of CTPA in the ED for cancer patients suspected to have PE. The objective of
this study is to assess the rate of positive PE by CTPA in the ED in cancer patients and the vari-
ables that are associated with positive results.
Methods: A retrospective review of electronic medical records for 208 consecutive patients
with cancer who presented to the ED and received a CTPA for suspected PE over a 12-month
period. The review included demographics, type and status of cancer, presenting symptoms,
CTPA results, calculation of Wells Score, management based on CT findings, and outcome of
patients.
Results: Among the 208 patients who met the inclusion criteria during our study period (mean
age 57 ± 13.37 years, 73% women, 59% African American, and 32% Caucasians), 5.7% were diag-
nosed with PE. One hundred and eighty-two (83.7%) had a Wells Score 64, of which 2.2% were
found to have to have PE, 22 (16.3%) patients had a Wells Score >4, of which 36.4% were found
to have PE (p < .0001). Sensitivity and specificity of Wells >4 was 66.7% and 92.9%, respectively,
with an odds ratio of 27 (95% CI 6.6–113.6). Receiver operator characteristics area under thene, Harper
132 P. Tannous et al.curve for Wells Score was 0.868. Age, race, sex, malignancy type, stage, status, clinical presen-
tation, D-dimer, and a previous history of venous thromboembolism were not found to have sta-
tistically significant predictive values.
Conclusion: The yield of CTPA to rule out PE in patients with cancer presenting in the ED is low.
Following a validated decision-making protocol such as Wells Criteria may significantly decrease
the number of CTPA used in the ED.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Cancer is a known risk factor for developing venous throm-
boembolism [1]. Population studies have shown that the
incidence of venous thromboembolic disease in cancer
patients ranges from 0.6% to 4.0% and is associated with
an increased risk of mortality [2–7]. One of the fatal com-
plications of venous thromboembolism is the development
of pulmonary embolism (PE). Khorana et al. [3] reported
that the mortality rates were 24.8% in cancer patients
who developed PE compared with 6.5% of patients that
did not have PE (p < .0001).
Early detection of PE and treatment with anticoagulation
has been shown to improve survival [8]. Clinical decision
rules, such as Wells Criteria, have been developed (and val-
idated) to aid in ruling out patients that do not have PE [9].
However, the use of clinical decision rules to exclude those
without PE is sporadically used [10]. There is ample evi-
dence that the use of computed tomography pulmonary
angiography (CTPA) in the emergency department (ED) for
patients suspected to have PE has been steadily rising in
the last 2 decades, which exposes patients to increased risks
with no significant detection of PE or change in outcomes
[11,12]. However, there are limited studies that specifically
address the use of CTPA in the ED for cancer patients sus-
pected to have PE. The aim of this study is to assess the rate
of positive PE by CTPA in the ED in this patient population
and the variables that are associated with positive results.Methods
Study design and setting
This is a retrospective analysis of a cohort of 208 patients
with a history of malignancy who presented to the ED of a
tertiary academic hospital with a comprehensive cancer
center and underwent CTPA to evaluate PE over 15 months.
The study protocol was approved by the Institutional Review
Board.
The inclusion criteria for the study were patients with a
known history of malignancy and who had a CTPA to assess
for PE in the ED. Patients excluded from the study were
those who did not have a history of malignancy, those diag-
nosed with a malignancy post-CTPA, patients in whom the
diagnosis of venous thromboembolism was only made with
a ventilation–perfusion scan, and/or Doppler venous study.
Patients that had insufficient data that would not allow cal-
culation of a Wells Score were also excluded from the study.Data collection and measurement
Patient demographics, presenting symptoms, documented
physical exam, type of cancer including current stage (local,
regional, distant, unstageable, unknown), disease status
(remission, relapse, new diagnosis), and treatment were
reviewed. Laboratory values, chest X-ray, and CTPA results
were also recorded. Hospital course was also reviewed
assessing for management of the patient, complications
from CTPA, and disposition. D-dimer results when available
were reviewed if they were obtained in the ED during initial
workup.
Wells Score was retrospectively calculated for each
patient from the collected data. While our population
included only patients with a history of malignancy, patients
whose disease was documented as in remission and who had
been without chemotherapy for >6 months were not
assigned 1 point for malignancy. Special consideration was
given to clinician suspicion for PE being the primary diagno-
sis in Wells Score. Patients meeting the following criteria
were assigned 3 points: (1) patients who were started on
anticoagulation prior to the CTPA; (2) patients that were
specifically sent to the ED for suspicion of PE; (3) documen-
tation from the physician stating that PE was equally likely
or most likely; (4) patients receiving ongoing anticoagula-
tion at the time of admission were given 3 points; (5)
patients with a history of deep vein thrombosis treated with
Greenfield filter in lieu of anticoagulation were also desig-
nated to receive 3 points but we had no incidence of this
in our study population. Patients that did not meet these
criteria were not given any points for PE being the primary
diagnosis in Wells Criteria.
The diagnosis of PE was confirmed by a pulmonary arte-
rial filling defect on CTPA with pulmonary protocol. All
CTPA with pulmonary protocol were reviewed by a board
certified radiologist. The CTPA was also reviewed for an
alternative diagnosis that may explain the patient’s
symptoms.
Complications from CTPA were assessed as contrast-
induced nephropathy, extravasation of contrast material,
and anaphylaxis from contrast material.
Data analysis
Continuous variables are presented with means and stan-
dard deviations. Categorical variables are summarized as
percentages. To assess the differences between PE-
positive and PE-negative patients in terms of Wells Criteria,
Fischer’s exact test was used with dichotomous value of
Table 1 Patient baseline clinical characteristics.
Characteristic N (%)
No. of patients 208
Demographics
Age, y (mean ± SD) 56.86 ± 13.7
Sex, n (%)
Male 57 (27.4)
Female 151 (72.6)
Pulmonary embolism in Emergency Department 133Wells Score 64 and >4 as dichotomous variables for low/-
moderate and high risk for PE, respectively. To retrospec-
tively assess the discrimination of Wells Criteria in cancer
patients, Wells Score performance was assessed by calculat-
ing the receiver operating characteristic curve. To deter-
mine if underlying malignancy or presenting complaints
had a significant association with the likelihood of PE logis-
tic regression was performed with positive or negative PE as
the dichotomous outcome.Race, n (%)
Black 123 (59.1)
White 67 (32.2)
Other 18 (8.7)
Previous PE or DVT 29 (13.9)
Antiplatelet agent use 36 (17.3)
Anticoagulation use 22 (10.6)
Presenting symptoms, n (%)a
Dyspnea 130 (62.5)
Lower extremity swelling 24 (11.5)
Hemoptysis 14 (6.7)
Abdominal pain 13 (6.3)
Leg pain 11 (5.3)
Syncope 6 (2.9)
Palpitations 5 (2.4)
Others 39 (18.7)
Underlying malignancy, n (%)
Lung 56 (26.9)
Breast 52 (25.0)
Hematological 24 (11.5)
Gynecological 22 (10.6)
Genitourinary 16 (7.7)
Abdominal 15 (7.2)
Head and neck 5 (2.4)
Others 18 (8.7)
Disease activity
Remission 87 (41.8)
Relapse 77 (37)
Ongoing initial treatment 44 (21.2)
Treatment status
Current chemotherapy 119 (57.2)
No active therapy 89 (42.8)
Disease stage
Local 50 (24.0)
Regional 48 (23.1)
Distant 86 (41.3)
Not stageable 6 (2.9)
Unknown stage 18 (8.7)
Note: DVT = deep vein thrombosis; PE = pulmonary embolism;
SD = standard deviation.
a Patient may have more than one presenting symptoms.Results
During our study period 208 patients met the inclusion crite-
ria and underwent CTPA with pulmonary protocol in the ED
to assess for PE. Table 1 presents the baseline characteris-
tics of these patients. The patients included in the study
were 57 men (27.4%) and 151 women (72.6%) with a mean
age of 56.86 ± 13.7 (years ± standard deviation). Sixty-
seven (32.2%) self-identified as Caucasian, 123 (59.1%)
African American, and 18 (8.7%) as others. The underlying
malignancies were primarily lung 56 (26.9%), breast 52
(25%), hematologic 24 (11.5%), and gynecological 22
(10.6%). In 87 (41.8%) of the study population the disease
was classified as in remission, 77 (37%) of these cases the
disease had relapsed, and 44 (21.2%) were new or recent
diagnoses. Stages of cancer in our study population were
classified as 50 (24%) local, 48 (23.1%) regional, 86 (41.3%)
distant, and 6 (2.9%) not stageable.
Twelve patients (5.7%) had acute PE based on the CTPA.
These patients were four (33.3%) men and eight (66.7%)
women. Their mean age was 55.5 years (standard devia-
tion ± 15.95) and six (50%) were African American and six
(50%) were Caucasian. The underlying malignancies in these
patients, were lung four (33.3%), breast three (25%),
endometrial two (16.7%), and one (8.3%) case of testicular,
prostate, and malignant thymoma. In seven (58.3%) of these
cases the disease had relapsed, three (25%) were classified
as in remission, and two (16.7%) were initial diagnoses.
Stages of cancer in patients with positive PE were classified
as two (16.7%) local, five (41.7% regional), and five (41.7%)
distant. Nine (75%) were undergoing current chemotherapy,
while three (25%) were not on active treatment.
To study the predictors of having a positive PE when per-
forming CTPA in the ED for patients with cancer, we
assessed the following variables: age, race, sex, malignancy
type, stage, status, Wells Score, clinical presentation, and
previous history of venous thromboembolism.
Only Wells Criteria significantly predicted the presence
of PE in these patients. Based on the Wells Criteria 182
(83.7%) were considered low risk (64) and 22 (16.3%) were
considered as high risk for PE (>4). Table 2 provides details
of the Wells Criteria in low- and high-risk groups. Among low
risk patients four (2.2%) were positive for PE compared with
eight (36.4%) in the high-risk group (p < .0001). The sensitiv-
ity of this score (Wells >4) was 66.7% and specificity was
92.9%, with a positive predictive value of 64% and a negative
predictive value (NPV) of 98%. The adjusted odds ratio (OR)
of PE with a Wells Score of >4 was 27.472 (95% confidence
interval (CI): 6.642–113.626, p < .0005). Receiver operating
characteristic area under the curve was 0.868 (Fig. 1). We
further analyzed the odds ratio (OR) for individual WellsScores (Table 3—only tachycardia (OR: 10.56, p < .05), clini-
cal assessment of PE as the most likely diagnosis (OR: 23.55,
p < .001) were found to have statistical significance.
D-dimer values were available for 60 patients—of these, 59
(98%) were positive based on our institutions lab reference
cut-off point. This limits the test discriminatory value in
the current study. Furthermore, to examine the potential
utility of alternative scoring systems in the assessment of
pretest probability of PE in our patient population we
Table 2 Frequency and percentages of Wells Criteria in low- and high-risk groups.
Wells 64 (n = 186)
n (%)
Wells >4 (n = 22)
n (%)
Clinical signs and symptoms of DVT (+3 points) 3 (1.6) 5 (22.7)
PE #1 diagnosis, or equally likely (+3 points) 4 (2.2) 15 (68.2)
HR >100 (+1.5 point) 93 (50) 19 (86.4)
Immobilization at least 3 d/surgery within 4 wk (+1.5 point) 7 (3.8) 2 (9.1)
Previous DVT/PE (+1.5 point) 20 (10.8) 9 (40.9)
Hemoptysis (+1.0 point) 9 (4.8) 2 (9.1)
Malignancy with treatment within 6 mo or palliative (+1.0 point) 159 (85.5) 22 (100)
Note: DVT = deep vein thrombosis; HR = heart rate; PE = pulmonary embolism.
Fig. 1 Receiver operator characteristics (ROC) curve for
Wells Criteria. Diagonal segments are produced by ties.
134 P. Tannous et al.calculated Khorona scores for each patient with the exclu-
sion of brain cancer and multiple myeloma patients for
whom the scoring system was not developed (n = 203). ThisTable 3 Unadjusted odds ratio (OR) for individual Wells Criteria
PE diagnosis equal or most likely
HR >100
Immobilization at least 3 d
Previously diagnosed DVT/PE
Hemoptysis
Malignancy/treatment within 6 mo/palliative
Clinical signs and symptoms of DVT
Note: CI = confidence interval; d = days; DVT = deep vein thrombosis;
* p < .05.
** p < .001.score is used to predict the risk of venous thromboembolism
in patients on chemotherapy and includes site of cancer,
platelet count, hemoglobin value, and/or use of erythro-
poiesis stimulating and body mass index [13]. Based on cal-
culated Khorona scores at the time of ED assessment, 46
patients (22.7%) were classified as low risk, 132 patients
(65%) as moderate risk, and 25 patients (12.3%) as high risk.
Chi-square analysis of the scoring system revealed no statis-
tically significant correlation between risk category and
presence of PE in our population (p = .776).
The complications related to performing CTPA in ED
were seen in four patients (3.4%) and were primarily related
to reversible increase in creatinine. The increase in crea-
tinine was seen in patients who did not have PE (3.4% vs.
0%, p = .51). None of these patients required renal replace-
ment therapy and there were no other complications such as
extravasation of iodine contrast, anaphylaxis, or death.
Five (2.4%) patients died during hospitalization. The mor-
tality was two of 12 (16.7%) in those who had PE and three
of 196 (1.5%) in those who did not have PE (p = 0.003).
Discussion
The goal of this study was to assess the rate of PE in cancer
patients who underwent CTPA in the ED and to determine
the variables associated with a positive study in this high-
risk population. We found the PE is rare in this situation
(5.7%) and that the high-risk Wells Score (>4) was the only
predictor among the variables assessed in predicting PE in
this patient population.for positive pulmonary embolism (PE).
OR 95% CI
23.5455** (6.42, 86.30)
10.5600* (1.34, 83.37)
3.4727 (0.37, 32.34)
1.2519 (0.26, 6.03)
2.1364 (0.24, 18.64)
1.5349 (0.19, 12.42)
0 (0, –)
HR = heart rate; mo = months.
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eral population of patients who underwent CTPA in the
ED. In a study by Crichlow et al. [14] 152 patients underwent
CTPA, and PE was diagnosed in 11.8%. One hundred and ten
patients (72%) had a low-risk Wells Score (64). Eight of
these (7%) had PE as compared with 10 of 42 (24%) patients
with a high-risk Wells Score (>4).
Another multicenter prospective study from 11 EDs
around the USA showed that imaging to rule out PE was per-
formed on 38% low-risk patients [15]. Imaging was avoidable
according to National Quality Forum measures in 32% of
patients. The authors concluded that adherence to estab-
lished diagnostic protocols is likely to result in significantly
fewer patients receiving unnecessary imaging with substan-
tially lower risk and savings.
This is the first study to our knowledge that focuses on
cancer patients in the ED and shows that CTPA is overused
in this patient population and that following a validated
decision-making protocol such as Wells Criteria may signifi-
cantly decrease the number of CTPA used in the ED. Another
important finding by this study is that Wells Criteria were
the only predictor of PE in this patient population. Other
factors such as the type of cancer, stage, disease status,
and treatment were not significant in predicting PE.
The criticism for Wells Score is that it is not entirely
objective and depends heavily on the clinical judgement.
Several studies have included additional steps to further
determine the likelihood of PE in ED including the addition
of D-dimer and PE rule-out criteria. One study has shown
that D-dimer in oncology patients suspected to have PE in
an urgent care setting was positive in 85% of patients with
confirmed PE. The NPV and sensitivity were 97% and 98%,
respectively. The specificity and positive predictive value
were 18% and 25%, respectively [16]. In another study, the
NPV of D-dimer in both cancer and noncancer patients was
100%. PE was ruled out by a negative D-dimer test in
494/1554 (32%) patients without cancer, and in 18/164
(11%) patients with a malignancy [17]. The authors con-
cluded that enzyme-linked immunosorbent assay D-dimer
appears safe to rule out PE in cancer patients but it is neg-
ative in only one of 10 patients at the usual cut-off value.
Therefore, the majority of cancer patients are likely to have
positive D-dimer and may require further testing. Our study
shows that using the Wells Criteria provides an additional
effective tool in the decision to pursue further diagnostic
studies such as CTPA. Further prospective studies on cancer
patients are needed to elucidate the role of these
approaches—including in combinations—in the decision pro-
cess of ordering CTPA in the ED in this patient population.
There are other potential benefits in obtaining a CT scan
in these patients including influencing further management,
which was reported in 16% of our patients, and detecting
other incidental findings as reported in other studies. The
finding of an alternative diagnosis by CTPA has been shown
to be common (43%) in one study. However therapeutic con-
sequences were reported in only 4.9% of these patients. The
authors emphasized that CTPA should remain principally to
confirm or exclude PE in high probability cases and not to
establish alternate diagnoses [18]. Another recent study
showed similar results with the majority of findings showing
limited clinical significance [19].Other concerns associated with the overuse of CTPA in
the ED include the cost of health services and use of
resources including increased length of stay in the ED. There
are also potential risks to patients such as allergic reaction,
radiation exposure, and contrast-induced nephropathy.
Although these complications were rare in our patient pop-
ulation (3.4%), other studies have shown that contrast-
induced nephropathy may be as high as 14% [20]. Our study
shows that even in cancer patients, following validated cri-
teria to pursue the diagnosis of PE has a significant NPV and
may result in avoiding a significant number of CTPA.
Knowledge of validated decision-making rules for pretest
probability of PE by emergency physicians has been shown
to be variable. In a survey of 555 emergency room clini-
cians, 68% indicated familiarity with rules, but only 50%
reported using them in more than half of the applicable
cases [10]. Also, a significant number of respondents could
not correctly identify key components of the decision-
making rules. Fifty-seven percent of all respondents indi-
cated use of ‘‘clinical gestalt” rather than a decision rule
in more than half of the cases. Our study and others have
repeatedly shown that decision-making rules such as Wells
Criteria correlate with the probability of PE. Healthcare sys-
tems should encourage their use in the clinical decision-
making process and incorporate such rules in the electronic
medical record order sets to drive ordering further investi-
gations such as CTPA. A recent study evaluated the imple-
mentation of an evidence-based computerized clinical
decision support on the use of CTPA in patients suspected
to have PE in the ED. The introduction of this system was
associated with decreased CTPA use (55% vs. 49%; absolute
difference: 6.3%; 95% CI: 1.0–11.6%; p = .02). There were
also fewer symptomatic venous thromboembolic events dur-
ing follow-up in patients with an initial negative diagnostic
evaluation for PE [21]. However, such initiatives should be
coupled with repeated educational programs since it has
been shown that a single educational intervention had no
effect on appropriate utilization rates for CTPA in ED [22].
The study provides an important insight on the evalua-
tion of PE in the ED in high-risk cancer patients. However,
it does have limitations. The retrospective nature of the
analysis limits our study in several ways. Calculation of
the Wells Score, specifically the allocation of points for
the ED physician’s assessment of the pretest probability of
PE, may be the most likely diagnosis. Recognizing that infer-
ring physician clinical assessment is difficult utilizing only
retrospective data, we intentionally established strict crite-
ria, as detailed above, in order to avoid overestimation of
the Wells Score. While this poses the opposite risk of under-
estimation in specific clinical scenarios, we find this accept-
able given the role Wells Criteria plays in potentially
avoiding unnecessary CTPE. We therefore prefer to err on
the side of lower scores to avoid increasing the apparent
sensitivity of the scoring system. Also, our study is limited
only to patients presenting to the ED for evaluation. Our
analysis of the OR for individual components of the Wells
Score revealed statistically significant results for tachycar-
dia and clinical suspicion of PE only; these results suggest
the potential benefit of further study with a larger popula-
tion to assess if individual factors or a combination of fac-
tors included in the criteria would provide simpler or more
136 P. Tannous et al.accurate predictive values but the low incidence of PE in
our study limits our power to address these questions.
We recognize that there is a substantial portion of
patients with history of malignancy who undergo evaluation
for PE on an entirely outpatient basis, and our study does
not purport to address this. The low incidence of PE in our
study population also decreases the likelihood of finding
alternative positive predictors of PE such as presenting
symptoms, age, or cancer type, etc. While we found no sta-
tistically significant positive predictive values or NPVs for
alternative variables, the low incidence of PE in our study
population limits our power to detect the effects these vari-
ables may contribute. Although the sample size is large, it
does reflect a single center experience. D-dimer was not
available in a large number of patients in this study, and
was 98% positive among the patients who received this test
limiting its discriminatory value. The design of our study
limits our ability to calculate cost-benefit analysis of CT-
PE in the ED. Further prospective, multicenter trials are
warranted to validate the current findings, address the
above issues, and study the role of other protocols in diag-
nosis of PE in cancer patients evaluated in the ED.
Conclusion
Our study shows that PE is rare in cancer patients who
undergo CTPA in the ED to rule out PE. Wells Criteria are
very good in predicting patients who are unlikely to have
PE in this patient population.
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